

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

MAY 18 2005

(use as many sheets as necessary)

Application Number	10/632,706
Filing Date	August 1, 2003
First Named Inventor	James D. Marks
Group Art Unit	<del>1645</del> 1645
Examiner Name	<del>MINNIFIELD</del> MINNIFIELD
Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
M	1.	4,689,299		Insel et al.	08/25/1987	
	2.	5,306,730		Nagai et al.	04/26/1994	
	3.	5,807,741		Brown et al.	9/15/1998	
	4.	5,919,665		Williams	07/06/1999	
	5.	5,932,449		Emanuel et al.	8/3/1999	
	6.	6,331,402		Nussbaum et al.	12/18/2001	
	7.	6,416,947		Balasubramanian et al.	07/09/2002	
	8.	6,495,143		Lee et al.	12/17/2002	
	9.	6,667,158		Bavari et al.	12/23/2003	
	10.	6,841,156		Aoki et al.	01/11/2005	
M	11.	2002/0155114		Marks	10/24/2002	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
M	12.	WO	00/69891		Dept of the Army	11/23/2000		
M	13.	WO	00/69895		Dept of the Army	11/23/2000		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
M	14.	Amersdorfer et al. (1997) <i>Infect. Immun.</i> , 65: 3743-3752	
M	15.	Amersdorfer et al. (2002) <i>Vaccine</i> 20: 1640-1648	
M	16.	Arnon (1993) Pp. 477-482 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
M	17.	Arnon et al. (2001) <i>J. Am. Med. Assoc.</i> 285: 1059-1070	

Examiner Signature	<i>N M Minnifield</i>	Date Considered	12-13-05
-----------------------	-----------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	1645
	Examiner Name	MINNIFIELD
	Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005	

	18.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
	19.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
	20.	Black and Gunn. (1980) <i>Am. J. Med.</i> , 69: 567-570	
	21.	Black, <i>et al.</i> (1980) <i>Am. J. Med.</i> , 69:567-570	
	22.	Black, <i>et al.</i> (1986) <i>J. Cell Biol.</i> , 103:521-534	
	23.	Bowmer (1963) <i>Bull. W. H. O.</i> 29: 701-709	
	24.	Byrne and Smith (2000) <i>Biochimie</i> 82: 955-966	
	25.	Chen <i>et al.</i> (1997) <i>Infect. Immun.</i> 65(5): 1626-1630	
	26.	Chen <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 2420-2425	
	27.	Colcher <i>et al.</i> (1990) <i>J. Natl. Cancer Inst.</i> 82: 1191-1197	
	28.	Daniels-Holgate <i>et al.</i> (1996) <i>J. Neurosci. Res.</i> 44:263-271	
	29.	Demarchi, <i>et al.</i> (1958) <i>Bull. Acad. Nat. Med.</i> , 142: 580-582	
	30.	Dolly <i>et al.</i> (1984) <i>Nature (London)</i> 307: 457-460	
	31.	Emanuel <i>et al.</i> (1996) <i>J. Immunol. Meth.</i> , 193: 189-197	
	32.	Fitzsimmons <i>et al.</i> (2000) <i>Vaccine</i> 19: 114-121	
	33.	Foote and Milstein (1991) <i>Nature</i> , 352:530-532	
	34.	Foote, <i>et al.</i> (1991) <i>Nature</i> 352: 530-532	
	35.	Fotinou <i>et al.</i> (2001) <i>J. Biol. Chem.</i> 276: 32274-32281	
	36.	Franz <i>et al.</i> (1993) Pp. 473-476 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
	37.	Gibson <i>et al.</i> (1988) <i>J. Appl. Bacteriol.</i> , 64: 285-291	
	38.	Gill (1982) <i>Microbiol. Rev.</i> 46: 86-94	
	39.	Hallis <i>et al.</i> (1993) Pp. 433-436 In: <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R., Plenum, New York	
	40.	Hathaway, <i>et al.</i> (1984) <i>J. Infect. Dis.</i> 150:407-412	

Examiner Signature		Date Considered	12-13-05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	<del>1645</del> 1645
	Examiner Name	<del>MINNIFIELD</del> MINNIFIELD
	Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005	














	41.	Hatheway (1995) <i>Curr. Top. Microbio. Immunol</i> , 195: 55-75	
	42.	Hatheway and Dang (1994) Pp. 93-107 In: <i>Therapy with Botulinum Toxin</i> , ed. Jankovic, J., Dekker, New York	
	43.	Hatheway <i>et al.</i> (1984) <i>J. Infect. Dis.</i> , 150: 407-412	
	44.	Hibbs <i>et al.</i> (1996) <i>Clin. Infect. Dis.</i> , 23: 337-340	
	45.	Hildebrand, et al. (1961) <i>Proc. Soc. Exp. Biol. Med.</i> 107-284-289	
	46.	Huston, et al., (1996) <i>J. Nucl. Med.</i> 40: 320	
	47.	Koriazova and Montal (2003) <i>Nat. Struct. Biol.</i> , 10: 13-18	
	48.	Kozaki <i>et al.</i> (1986) <i>Infect. Immun.</i> , 52: 786-791	
	49.	Kozaki <i>et al.</i> (1995) <i>Microbiol. Immunol.</i> , 39: 767-774	
	50.	Kozaki <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 4811-4816	
	51.	Lacy and Stevens (1999) <i>J. Mol. Biol.</i> 291: 1091-1104	
	52.	Lacy <i>et al.</i> (1998) <i>Nat. Struct. Biol.</i> 5: 898-902	
	53.	Lang, et al. (1993) <i>J. Immunol.</i> 151: 466-473	
	54.	Mahant <i>et al.</i> (2000) <i>J. Clin. Neurosci.</i> 7: 389-394	
	55.	Middlebrook and Franz (1997) Botulinum Toxins, chapter 33. In F.R. Sidell, E.T. Takafuji, D.R. Franz (eds.), <i>Medical Aspects of Chemical and Biological Warfare</i> . TMM publications, Washington, D.C.	
	56.	Middlebrook, et al. (1995) <i>Curr. Top. Microbiol. Immunol.</i> 195:89-122	
	57.	Montecucco (1986) <i>Trends Biochem. Sci.</i> 11:314-317	
	58.	Montecucco and Schiavo (1995) <i>Q. Rev. Biophys.</i> 28: 423-472	
	59.	Montero-Julian <i>et al.</i> (1995) <i>Blood</i> 85: 917-924	
	60.	Mullaney <i>et al.</i> (2001) <i>Infect. Immun.</i> 69: 6511-6514	
	61.	Nowakowski <i>et al.</i> (2002) <i>Proc. Natl. Acad. Sci. U S A</i> , 99: 11346-11350	
	62.	Oguma <i>et al.</i> (1990) <i>Lancet</i> 336: 1449-1450	

Examiner Signature		Date Considered	12-13-05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	<del>1645</del> 1645
	Examiner Name	<del>MINNIFIELD</del> MINNIFIELD
	Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005	

	63.	Pless et al. (2001) <i>Infect. Immun.</i> 69: 570-574	
	64.	Reichert (2001) <i>Nat. Biotechnol.</i> 19: 819-822	
	65.	Schengrund (1999) <i>J Toxicol Toxin Rev.</i> , 18: 35-44	
	66.	Schiavo et al. (1992) <i>Nature (London)</i> 359: 832-835	
	67.	Schiavo et al. (1993) <i>J. Biol. Chem.</i> 268: 23784-23787	
	68.	Schier et al. (1995) <i>Immunotechnology</i> , 1: 73-81	
	69.	Siegel (1988) <i>J. Clin. Microbiol.</i> 26: 2351-2356	
	70.	Simpson (1980) <i>J. Pharmacol. Exp. Ther.</i> 212: 16-21	
	71.	Sonnabend et al. (1981) <i>J. Infect. Dis.</i> , 143: 22-27	
	72.	Tacket et al. <i>Am. J. Med.</i> , 76: 794-798	
	73.	Volk et al. (1984) <i>Infect. Immun.</i> 45: 604-609	
	74.	Williams et al. (1983) <i>Eur. J. Biochem.</i> , 131: 437-445	
	75.	Zwick et al. (2001) <i>J. Virol.</i> 75: 12198-12208	

Examiner Signature		Date Considered	12-13-05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	1645
		Examiner Name	<del>MINNIFIELD</del>
		Attorney Docket Number	407T-895120US
		Date Submitted	October 7, 2005

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	2004/0265935 A1		Atassi	12/30/2004	
	2	2004/0175385 A1		Marks et al.	09/09/2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
	3	HALL (2004) Journal of Immunological Methods 288, pp. 55-60		
	4	OSHIMA (1997) Molecular Immunology Vol. 34, No. 14, pp. 1031-1040		

Examiner Signature	<i>NM Minnifield</i>	Date Considered	12/13/05
-----------------------	----------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.